CAS:160003-66-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
是一种不可逆的 PARP1 抑制剂,可用于三阴性乳腺癌的研究。
Array ( [133] => Array ( [id] => 133 [name] => Inhibitors & Antagonists & Agonists [num] => [children] => Array ( [352] => Array ( [id] => 352 [name] => Protein Tyrosine Kinase/PTK ) [350] => Array ( [id] => 350 [name] => PI3K/Akt/mTOR ) [351] => Array ( [id] => 351 [name] => Endocrinology & Hormones ) [357] => Array ( [id] => 357 [name] => Angiogenesis ) [358] => Array ( [id] => 358 [name] => HIF ) [363] => Array ( [id] => 363 [name] => Immunology & Inflammation ) [364] => Array ( [id] => 364 [name] => Stem Cells ) [365] => Array ( [id] => 365 [name] => Apoptosis ) [377] => Array ( [id] => 377 [name] => Metabolic Enzyme & Protease ) [379] => Array ( [id] => 379 [name] => Autophagy ) [380] => Array ( [id] => 380 [name] => ER Stress ) [384] => Array ( [id] => 384 [name] => Cell Cycle ) [385] => Array ( [id] => 385 [name] => Cytoskeleton ) [386] => Array ( [id] => 386 [name] => DNA Damage & DNA Repai ) [387] => Array ( [id] => 387 [name] => Epigenetics ) [388] => Array ( [id] => 388 [name] => Ubiquitin ) [389] => Array ( [id] => 389 [name] => JAK/STAT ) [390] => Array ( [id] => 390 [name] => GPCR & G Protein ) [391] => Array ( [id] => 391 [name] => Neuronal Signal Pathway ) [392] => Array ( [id] => 392 [name] => MAPK ) [393] => Array ( [id] => 393 [name] => NF-κB ) [394] => Array ( [id] => 394 [name] => Membrane Transporter & Ion Channel ) [395] => Array ( [id] => 395 [name] => TGF-β/Smad ) [396] => Array ( [id] => 396 [name] => Hippo ) [775] => Array ( [id] => 775 [name] => Antibody-drug Conjugate/ADC Related ) [122] => Array ( [id] => 122 [name] => Others ) ) ) )
>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Cell Cycle >
IniparibCAS:160003-66-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
CAS | 160003-66-7 |
English Name | Iniparib |
Synonyms | BSI-201;3-硝基-4-碘苯甲酰胺 |
Molecular Formula | C7H5IN2O3 |
Molecular Weight | 292.03 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | Light yellow to yellow Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 685-396-9 |
MDL | MFCD11110639 |
SMILES | O=C(C1=CC=C(C([N+]([O-])=O)=C1)I)N |
Target Point | PARP |
Passage | Cell Cycle;DNA Damage/DNA Repair; Epigenetics |
Background | Iniparib/BSI-201 is an irreversible PARP1 inhibitor for the study of triple-negative breast cancer. |
Biological Activity | Iniparib是一种不可逆的 PARP1 抑制剂,可用于三阴性乳腺癌的研究。Iniparib非选择性地修饰肿瘤细胞中含半胱氨酸的蛋白质。[1-3] |
In Vitro | Iniparib(100μM)弱抑制SSB修复,抑制可以通过敲低PARP1来逆转[2]。 Iniparib与顺铂联合应用对Myc/MDA-231具有EMT变化的细胞毒性[3]。 |
Cell Experiment | 将MDA-MB-436和MDA-MB-231细胞分别以2000和500个细胞/孔接种在96孔板中,并用veliparib,cmpd-A,cmpd-C,Iniparib或Iniparib-met在0,0.0001,0.01,0.1,1或10μM下持续9天。对于5天的细胞增殖测定,将MDAMB-231和MDA-MB-436细胞分别以1000和4000个细胞/孔接种在96孔板中,并用Iniparib或Iniparib-met以0.10,0.3,1,100处理,在0,1.8,3.75或7.5μMBSO存在下3或10μM,持续5天。将DLD1 +/+和DLD1 - / - 细胞以1000个细胞/孔接种于96孔板中,并在0,0.003,0.05,0.05,0.01,0.03,0.1,0.3或1mM的存在下用TMZ处理0,0.005,0.05,0.5或5μM的veliparib,或Iniparib,共5天。处理后,进行细胞滴度发光[1]。 |
Data Literature Source | [1]. Liu X,et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23. [2]. Ma W,et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5. [3]. Yin S,et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12(8):e0183578. |
Unit | Bottle |
Specification | 10mg 50mg 100mg |
是一种不可逆的 PARP1 抑制剂,可用于三阴性乳腺癌的研究。